European Medicines Agency Committee Recommends Six New Medicines, Five Expanded Indications

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued positive opinions for six new medicines and recommended five extensions of therapeutic indications for existing products between October 12 and 15, 2026. Notably, daraxonrasib (branded Rasonque) received a positive opinion for adults with metastatic pancreatic adenocarcinoma who have failed at least one prior line of therapy.